A Comprehensive Hepatitis B Surface Antigen-Positive Patient-Centered Screening and Linkage to Care Strategies Targeting Microelimination of Hepatitis C Virus Infection in Chongqing, China
Table 1
General demographic characteristics of cases with HBsAg and anti-HCV antibody positive (N = 44).
Variables
No. of cases %
HCV-RNA positive
Sex (n = 44)
Male
32 (72.7%)
14 (82.4%)
Female
12 (27.3%)
3 (17.6%)
Age (n = 44)
21∼30
1 (2.3%)
0 (0%)
31∼40
7 (15.9%)
3 (17.6%)
41∼50
23 (52.3%)
9 (52.9%)
51∼60
10 (22.7%)
2 (11.8%)
61∼70
3 (6.8%)
3 (17.6%)
HBV status (n = 44)
HBsAg+, HBeAg+, anti-HBc+
4 (9.1%)
1 (25%)
HBsAg+, HBeAb+, anti-HBc+
39 (88.6%)
16 (41.0%)
HBsAg+, and anti-HBc+
1 (2.3%)
0
Duration of HBV therapy in patients receiving anti-HCV therapy (n = 20)
Before anti-HCV therapy
8
Simultaneously with anti-HCV therapy
3
After HCV therapy
2
Not start HBV therapy
7
Liver cirrhosis status (n = 40)
Decompensated cirrhosis
10
Compensated cirrhosis
7
No liver cirrhosis
23
Genotype (n = 21)
GT1
5
GT2
1
GT3
6
GT6
5
No amplification
4
Probable infection routes (n = 38)
Intravenous drug use
10 (26.3%)
6 (60.0%)
Blood-borne
1 (2.6%)
1 (100.0%)
Surgery history
13 (34.2%)
5 (38.5)
Tooth extraction history
1 (2.6%)
0
Sexual transmission
2 (5.3%)
1 (50.0%)
Transfusion
8 (21.1%)
3
Dental treatment history
1 (2.6%)
1 (100.0%)
Hemodialysis
1 (2.8%)
0
Unknown
11 (28.9%)
2 (18.2%)
Treatment history (n = 20)
Others
9 (45.0%)
SOF + DCV ± RBV
2 (10.0%)
SOF/VEL ± RBV
3 (15.0%)
Elbasvir/grazoprevir
2 (10.0%)
IFN + RBV
1 (5.0%)
SOF + RBV
2 (10.0%)
Ledipasvir/sofosbuvir
1 (5.0%)
SOF = sofosbuvir; DCV = daclatasvir; VEL = velpatasvir; IFN = interferon; RBV = ribavirin.
